[1] MASAKAZU ISHII . Inhibitory Effect of Lomerizine, a Prophylactic Drug for Migraines, on Serotonin-Induced Contraction of the Basilar Artery[J]. Journal of pharmacological sciences, 2009, 111 2: Pages 221-225. DOI:
10.1254/jphs.09205sc[2] HIDEAKI HARA Masamitsu S Nobuko Toriu. Clinical Potential of Lomerizine, a Ca2+ Channel Blocker as an Anti-Glaucoma Drug: Effects on Ocular Circulation and Retinal Neuronal Damage[J]. Cardiovascular Therapeutics, 2006, 22 3: 199-214. DOI:
10.1111/j.1527-3466.2004.tb00141.x[3] MASAKAZU ISHII. Neuroprotection by lomerizine, a prophylactic drug for migraine, against hydrogen peroxide-induced hippocampal neurotoxicity.[J]. Molecular and Cellular Biochemistry, 2011, 358 1-2: 1-11. DOI:
10.1007/s11010-011-0913-3[4] DONNA L. SAVIGNI . Three Ca2+ channel inhibitors in combination limit chronic secondary degeneration following neurotrauma[J]. Neuropharmacology, 2013, 75: Pages 380-390. DOI:
10.1016/j.neuropharm.2013.07.034[5] LUAN T. TRAN. The voltage-gated calcium channel blocker lomerizine is neuroprotective in motor neurons expressing mutant SOD1, but not TDP-43[J]. Journal of Neurochemistry, 2014, 130 3: 455-466. DOI:
10.1111/jnc.12738[6] RYAN L. O’HARE DOIG . Specific combinations of ion channel inhibitors reduce excessive Ca2+ influx as a consequence of oxidative stress and increase neuronal and glial cell viability in vitro[J]. Neuroscience, 2016, 339: Pages 450-462. DOI:
10.1016/j.neuroscience.2016.10.005